Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(2,6-difluorobenzyl)-4-sulfamoylbenzamide is a small molecule sulfonamide derivative featuring a benzamide moiety linked to a difluorobenzyl group. It is primarily studied as an inhibitor of carbonic anhydrase II (CA II), an enzyme involved in the reversible hydration of carbon dioxide. Sulfonamides like this compound are known for their antibacterial properties and have been explored for various therapeutic applications due to their ability to inhibit enzymes such as dihydropteroate synthase and carbonic anhydrases. The presence of fluorine atoms enhances its lipophilicity and metabolic stability[5][8]. This compound has been used mainly as a research tool or discovery agent rather than as an approved pharmaceutical product[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(2,6-difluorobenzyl)-4-sulfamoylbenzamide.